The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential as such a target, we constructed an oncolytic adenovirus with Retargeted Infectivity Via EGFR (Delta-24-RIVER) on the backbone of Delta-24. This new oncolytic adenovirus targets, as Delta-24 does, the disrupted Rb pathway in cancer cells; in addition, this adenovirus has also been retargeted through the abrogation of CAR binding (Y477A mutation in adenoviral fiber protein) and insertion of an EGFRvIII-specific binding peptide in the HI loop of the fiber protein. As compared with Delta-24, Delta-24-RIVER induced EGFRvIII-selective cytotoxicity in U-87 MG isogenic cell lines and in tetracycline-inducible EGFRVIII expressing U-251 MG cells. Accordingly, by tittering the viral progeny and examining fiber protein expression in the above cells, we showed that the replication of this new construct also correlated with EGFRvIII expression. Consistently, immunohistochemistry staining of the adenoviral capsid protein hexon in the virus-treated tumors revealed that the virus replicated more efficiently in EGFRvIII-expressing U-87 MG.DEGFR xenografts than in the tumors grown from U-87 MG cells. Importantly, treatment with Delta-24-RIVER prolonged the survival of animals with intracranial xenografts derived from U-87 MG.DEGFR cells. Therefore, our results constitute the first proof of the direct targeting of a cancer-specific receptor using an oncolytic adenovirus.
Introduction
Glioblastoma multiforme (WHO (World Health Organization) grade IV), the most frequent histological type of primary brain tumor, accounts for 69% of all astrocytic and oligodendroglial tumors.
1 Median survival is generally less than 1 year from the time of diagnosis, with a life expectancy of 2 years at the most in patients with the most favorable disease characteristics. 2 Recent advances in our understanding of brain tumor biology have suggested that treatment strategies that target molecular defects in the tumors will provide the most effective and selective therapies. 3, 4 One of the most common molecular abnormalities in glioblastomas is amplification of the epithelial growth factor receptor (EGFR) gene, which exists in B40% of primary glioblastomas. 1 In addition, EGFR amplicons are often mutated, with the most frequent type (450%) consisting of the variant Delta or III (EGFRvIII or Delta-EGFR) mutation, which comprises the deletion of exons 2-7.
1,5 Importantly, this deletion generates a unique epitope in the extracellular component of the protein that is not present in normal cells and may be used as a cancer-specific target. 5 Adenovirus-mediated oncolysis is a rapidly growing field that could lead to the development of novel and more effective anticancer therapies. 4, 6, 7 One problem that is hindering the development and application of this therapy is the varied tropism of the adenovirus resulting from the widespread distribution of its primary cellular receptor the coxsackie and adenovirus receptor (CAR). Of particular pertinence in gliomas is that most glioma cells are not optimum targets because they express low levels of CAR. 7 Moreover, normal tissues express high levels of CAR, with the result that the administration of oncolytic adenoviruses could result in potential uncontrolled infection and toxicity. 8 Therefore, strategies capable of CAR-independent infectivity and of retargeting the virus to cancer-specific receptors are required to improve the therapeutic index of oncolytic adenoviruses in gliomas. In one effort to overcome the problem, we have constructed a replication-competent adenovirus with Retargeted Infectivity Via EGFR (Delta-24-RIVER) and tested its infectivity, selectivity and efficacy in glioma cells in vitro and in vivo.
Methods

Cell lines and tissue culture
The human malignant glioma cell lines U-87 MG and U-251 MG and human lung carcinoma cell line A549 were obtained from the American Type Culture Collection (Manassas, VA). U-87.wtEGFR and U-87.DEGFR cell lines were kind gifts from Dr WK Cavenee (Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA). 9 The U-251.E18 cell line was a generous gift from Dr AA Habib (The University of Texas Southwestern Medical Center, Dallas, TX). 10 Cell lines were maintained in DMEM/F12 supplemented with 10% fetal bovine serum, 100 mg ml À1 penicillin and 100 mg ml À1 streptomycin in a humidified atmosphere containing 5% CO 2 at 37 1C. 293F28 and U-251.E18 cells were cultured in the same medium containing 100 mg ml
À1
Zeocin. 10, 11 In addition, U-251.E18 cells were maintained in the presence or absence of tetracycline (1 mg ml
) to repress or activate, respectively, the expression of EGFRvIII. 10 Peptide-binding assay The peptide (5-carboxyfluorescein)-HFLIIGFMRRALC-GA was synthesized by SynPep (Dublin, CA). For peptide binding, cells were detached and dissociated using 0.05% EDTA in phosphate-buffered saline (PBS) by pipetting. After this, 10 6 cells were resuspended and blocked in 200 ml of PBS containing 10% normal goat serum and 5% bovine serum albumin for 20 min at 25 1C with shaking at 100 r.p.m. Then, the cells were pelleted and resuspended in PBS containing 1% bovine serum albumin and 1 mM peptide and incubated at 25 1C for 30 min with shaking at 100 r.p.m. Afterwards, the cells were washed once with 1% bovine serum albumin in PBS and fixed with 4% paraformaldehyde in PBS for 10 min at 25 1C. Finally, cells were washed twice with PBS and resuspended in 500 ml of PBS. The binding of the peptide on the cell surface was analyzed with flow cytometry (FACSCalibur; Becton Dickinson, San Jose, CA).
Delta-24-RIVER construction and adenoviral infection
Delta-24-RIVER was generated by genetically modifying the adenovirus serotype 5, as depicted in Figure 1d . First, a duplex of oligonucleotides (5 0 -ACAACTGGATCTTC ACACTTCCTGATCATTGGATTCATGCGTCGCGC ACTTTGCGGTGCGGGATCATCTCC-3 0 and 5 0 -GGA GATGATCCCGCACCGCAAAGTGCGCGACGCAT GAATCCAATGATCAGGAAGTGTGAAGATCCAG TTGT-3 0 ) encoding the earlier described EGFRVIIIbinding peptide, PEPCH1, 13 was cloned within the HI loop of the knob domain, flanked by GSS flexible linkers. Specifically, the sequence was inserted into the EcoRV site of pXKÄ HI, a shuttle vector designed to introduce the modifications in the HI loop of the fiber protein. 14 Second, a Y477A mutation was introduced using the QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) to abrogate the binding of the viral fiber to the native receptor CAR, as described earlier, 12 resulting in the generation of pXKDHI.vIII. The Delta-24 deletion 6, 7 was introduced into the adenoviral backbone through the homologous DNA recombination in Escherichia coli BJ5183 (Stratagene) of the E1 fragment from pXC1-Delta-24 6 and the ClaI-linearized pVK500C, 15 which yielded the pVK.Delta-24 plasmid. The final adenoviral genome was generated by the homologous DNA recombination of pXKDHI.vIII and SwaI-linearized pVK500C.Delta-24 in E. coli BJ5183. To rescue the Delta-24-RIVER virus, the resulting viral backbone vector was digested with PacI and then transfected into 293F28 cells, a cell line expressing high levels of wild-type viral fiber, 11 which helps in the first round of viral production. The virus was then propagated in A549 cells. The mutant E1A region and the fiber modification were confirmed by PCR and restriction analysis, as described earlier, 16 and sequencing.
Flow cytometry
Suspensions of U-87 MG isogenic cells (2-5 Â 10 5 cells) were first treated with FcR blocking reagent (Miltenyi Biotec, Auburn, CA) to block the unwanted binding of antibodies to the cells and then incubated with fluorescein isothiocyanate-conjugated anti-human EGFR antibody (1:100; Calbiochem, La Jolla, CA) for 30 min at 4 1C. The expression levels of CAR and integrin avb5 were determined as described earlier. 17 We used conjugated IgG isotypes as negative controls. Samples were analyzed using FACSCalibur.
Cell viability assay
Cell viability was analyzed by crystal violet staining. 16 Real-time PCR Total RNA was isolated and reverse-transcribed using reverse transcriptase, and quantitative PCR analysis was performed on a chromo 4 sequence-detection system (BioRad, Hercules, CA, USA) using a SYBR-green PCR master mix (Applied Biosystems, Foster City, CA), and the following specific primers for fiber (forward: ) for 24 h. Actin was used as a loading control. (b) EGFR expression in the U-87 MG isogenic cell system. Levels of expression were analyzed by flow cytometry after exposure of the cultures to an antibody that recognizes both the wild-type and variant mutant form of EGFR. Note that U-87.EGFR and U-87.DEGFR cells expressed similar levels of EGFR or EGFRvIII, respectively, on their surface. (c) Testing of the EGFRvIII-binding peptide to the isogenic U-87 MG system. Representative findings from the peptide-binding assay performed in the three U-87 MG cell lines differing in their EGFR/EGFRvIII expression are shown. For this assay, PECPH1 peptide linked to carboxyfluorescein was synthesized. Cultures were exposed to 1 mM of the peptide, as explained in the Methods section, and analyzed for fluorescence levels using a flow cytometer. Note that PCEPH1 preferentially bound to EGFRvIII-overexpressing U-87 MG cells. (d) Schematic representation of the genetic modifications introduced into the backbone of adenovirus serotype 5. The Delta-24-RIVER genome contains three modifications: a mutant E1A adenoviral region, consisting of 24-bp deletions in the Rb-binding region; 6,7 a Y477A mutation in the loop of the fiber, which is critical for binding to CAR 12 and the coding sequence for the EGFRvIII-binding PEPCH1 peptide. 13 NeoMarkers Inc., Fremont, CA), EGFR and actin (Santa Cruz Biotechnology, Santa Cruz, CA). Protein bands were visualized using an ECL Western Blotting Detection System (GE Healthcare, Amersham Bioscience, Pittsburgh, PA).
Animal studies
To assess in vivo tropism, human glioma cells, either U-87 MG (5 Â 10 5 ) or U-87.DEGFR (2.5 Â 10 5 ) cells, were engrafted in the caudate nucleus of athymic mice, as described earlier, 7 and on days 3, 5 and 7 after cell implantation, animals were locally treated (5.5 Â 10 7 p.f.u. per dose) with intratumoral injections of Delta-24-RIVER. Animals were killed 18-20 days after cell implantation and their brains were studied for viral protein expression.
To assess the in vivo anticancer effects of Delta-24-RIVER, human glioma cells (10 5 cells) were intracranially implanted in athymic mice, and Delta-24-RIVER-or UVinactivated adenovirus was administered locally (5.5 Â 10 7 p.f.u. per dose, five doses) starting 3 days later. Any animal showing generalized or localized symptoms of toxicity was killed. Surviving animals were killed 61 days after cell implantation. The brains of the mice were removed, fixed in 4% formaldehyde for 24 h at room temperature and embedded in paraffin. Hematoxylineosin-stained sections were evaluated for evidence of tumor, necrosis and viral nuclear inclusions. Animal studies were performed in veterinary facilities at The University of Texas MD Anderson Cancer Center, Houston, TX, in accordance with institutional guidelines.
Immunohistochemistry
Paraffin-embedded sections of mouse brain tumor were analyzed for expression of the adenoviral protein hexon by immunohistochemistry, as described earlier. 7 Briefly, after antigen retrieval, sections were probed with rabbit polyclonal anti-hexon (1:150 dilution; Chemicon, Temecula, CA), counterstained with hematoxylin (Sigma, St Louis, MO), and mounted on Immu-mount (Thermo Shandon Inc., Pittsburgh, PA) after washing.
Statistical analysis
The in vivo anticancer effect of different treatments was assessed by plotting survival curves according to the Kaplan-Meier method, and groups were compared using the log-rank test.
Results
Construction of EGFRvIII-retargeted Delta-24
To test the possibility of constructing an EGFRvIIIretargeted adenovirus, we first tested the specificity of a small peptide PECPHC1 that was shown earlier to bind preferentially to EGFRvIII in pull-down assays or to bind to immobilized recombinant proteins. 13 To this end, we selected two glioma isogenic cell systems that differed in their EGFR/EGFRvIII expression. The first isogenic system was a U-87 MG system consisting of parental (low EGFR expression), U-87.wtEGFR (high EGFR expression) and U-87.DEGFR (high EGFRvIII expression) cells, as shown by western blotting and fluorescenceactivated cell sorting (FACS) analysis (Figures 1a and b) . Of interest, the overexpression of EGFR and EGFRvIII in the cellular membrane was of similar intensity in this system, as shown by FACS analysis (Figure 1b) . In the second isogenic cell system, a tetracycline-inducible system was used to induce EGFRvIII expression in U-251 MG cells (Jiang et al. 10 and Figure 1a ). The ability of the 5-FAM-PECPHC1 peptide to bind to EGFRvIII in vivo was analyzed in the U-87 MG isogenic system by exposing cultures to the peptide and analyzing the fluorescence levels by FACS analysis. The binding to EGFRvIII was around 5-and 2.5-fold higher than the binding to EGFR in parental or EGFR-overexpressing U-87 MG cells, respectively (Figure 1c) . We concluded from these results that, as noted earlier in in vitro experiments, 13 the peptide preferentially binds in a living cell to the mutant variant of EGFR.
Delta-24-RIVER was constructed as described in Methods and depicted in Figure 1d . The virus encompasses three genetic modifications on the backbone of adenovirus serotype 5 to allow for selective infectivity and replication. The selective replicative phenotype is based on the generation of a 24-bp deletion in the E1A gene, similar to the mutation in Delta-24 described elsewhere. 6 This mutation disables the binding of E1A to the cellular Rb protein, thereby halting viral replication in quiescent Rb-competent cells. The selective infectivity is achieved by two genetic modifications: the insertion of the coding sequence for the PEPHC1 peptide in the HI loop of the adenoviral fiber protein and the earlier described Y477A mutation in the knob of the fiber protein, which abrogates the binding to CAR 12 ( Figure 1d ). Thus, this new oncolytic adenovirus is designed to preferentially infect cells expressing EGFRvIII and to selectively replicate in cancer cells with a disrupted Rb pathway.
Delta-24-RIVER-induced selective cytotoxicity of EGFRvIII-expressing glioma cells To determine whether Delta-24-RIVER-induced cytotoxicity is related to EGFRvIII expression rather than the expression of native adenoviral receptors, such as CAR and integrins, 19 we first examined the expression of these proteins on the cell surface using flow cytometry. The isogenic cells derived from U-87 MG cells expressed low levels of CAR (o30% of the examined cells), as did the parental cell line, whereas the U-251 MG-derived cells (U-251.E18) expressed high levels of the native receptor (475%), similar to the levels of expression observed in the parental cells. As expected, all cell lines expressed high levels of integrin avb5 (480%) on their surface (Figure 2a) . 7 To determine the oncolytic power of Delta-24-RIVER, we performed dose-dependence assays in which both isogenic systems (that is, high-CAR-and low-CARexpressing cell lines) were infected with Delta-24 or Delta-24-RIVER. Delta-24-RIVER displayed a specific oncolytic effect in EGFRvIII-expressing cancer cells independent of the levels of CAR expression. That is,
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Delta-24-RIVER had a complete CPE, at 10 p.f.u. per cell, on the U-87.DEGFR monolayer, but less than a 30% CPE on U-87.wtEGFR and U-87 MG cultures (Figure 2b) . Consistently, Delta-24-RIVER induced a complete CPE at a dose of 5 p.f.u. per cell in U-251.E18 cells cultured in the presence of tetracycline but had almost no effect on U-251.E18 cells cultured in the absence of tetracycline (Figure 2c ). Of importance, in cells expressing low levels of CAR (that is, U-87 MG cells), Delta-24-RIVER was more efficient in causing CPE in EGFRvIII-expressing cells than was Delta-24.
Taken together, our data demonstrate that Delta-24-RIVER-mediated oncolysis was selective for EGFRvIII expression and independent of CAR expression, and that the retargeted oncolytic adenovirus was more potent than untargeted Delta-24 adenovirus in EGFRvIIII-and low-CAR-expressing cells.
Replication of Delta-24-RIVER in EGFRvIII-expressing glioma cells
As oncolytic adenoviruses induce cell death through viral replication and eventually lysis of the host cell, 6 we next determined whether the EGFRvIII-specific cytotoxicity induced by Delta-24-RIVER was related to increased adenoviral replication by performing a titration assay of the viral progeny. In both isogenic systems, we observed that Delta-24-RIVER replication was related to EGFRvIII expression. That is, the replication efficiency of Delta-24-RIVER in U-87.DEGFR cells was two-and four-fold more potent than that in U-87.wtEGFR and U-87 MG cells, respectively (Figure 3a) . A similar positive relationship between selective CPE and adenoviral replication was observed in the U-251 MG-derived cells in which EGFRvIII expression was induced by the tetracycline-inducible system. Specifically, the replication efficiency of Delta-24-RIVER was 50-and 70-fold higher in the U-251.E18 cells expressing EGFRvIII (that is, cultured in the presence of tetracycline) than in the EGFRvIII-negative U-251.E18 cells (that is, cultured in the absence of tetracycline) and parental U-251 MG cells, respectively (Figure 3b) .
Using fiber protein expression as an indicator of adenoviral replication, we also examined viral fiber levels. Thus, by performing real-time PCR, we observed that fiber mRNA levels were 22.2 ± 3.4 and 9.5 ± 1.3 higher in Delta-24-RIVER-infected U-87.DEGFR and U-87.wtEGFR cells, respectively, than in the parental culture (Figure 3c ). These results were confirmed by western blotting studies. Specifically, at 36 and 48 h after viral infection in both U-87 MG isogenic and tetracyclineinducible U-251 MG cells, the fiber protein levels correlated with adenovirus-mediated CPE and replication (Figures 3d and e) . Collectively, these results showed that the replication efficiency of Delta-24-RIVER was related suggests, as we reported earlier, the existence of a wave of oncolytic viral spread around and within the tumor. However, in the parental U-87 MG tumors, few cells were hexon positive (Figure 4a ). These results indicate that Delta-24-RIVER replicates more efficiently in glioma cells expressing EGFRvIII, as we also observed in the in vitro experiments. Next, we examined the efficacy of Delta-24-RIVER in the treatment of EGFRvIII-expressing U-87 MG cells. In this study, EGFR-expressing xenografts were grown in the brains of athymic mice, and mice were then treated with Delta-24-RIVER (n ¼ 12) or UV-inactivated Delta-24-RIVER (n ¼ 10). Animals were killed when they began to exhibit signs of generalized or localized disease. We observed that Delta-24-RIVER treatment resulted in the prolonged survival of glioma-bearing animals (mean survival time, 26.1 days) compared with animals treated with the control adenovirus (mean survival time, 14 days; log-rank test o0.0001). Of significance, although all control animals died by day 14 of the experiment, 2 of the 12 (17%) Delta-24-RIVER-treated mice were still alive Oncolytic adenovirus retargeted to EGFRvIII Y Piao et al without noticeable neurologic deficits at the end of the study (day 61) (Figure 4b ). Thus, we conclude that Delta-24-RIVER replicates preferentially in EGFRvIII-expressing glioma cells in vivo and induces a significant therapeutic effect in animals with intracranial tumors derived from these cells.
Discussion
This study is the first to show the anti-glioma effect of an oncolytic adenovirus, Delta-24-RIVER, targeting both the prototype tumor suppressor gene Rb and the most relevant oncogene EGFR and its mutant variant III in malignant brain tumors. To construct the virus, we used detargeting strategies to ablate CAR binding 12 and modified the HI loop to incorporate the sequence of a peptide shown earlier to interact with EGFRvIII. 13 We showed that Delta-24-RIVER efficiently infects low CAR-expressing/high EGFRvIII-expressing glioma cells in vitro and in vivo. Using several systems of isogenic glioma cell lines with different expressions of EGFR and EGFRvIII, we demonstrated that expression of the mutant cancer receptor was sufficient to sensitize glioma The intracranial implantation of glioma cells was followed by adenoviral intratumoral injection, as explained in the Methods section (arrows, treatment doses). The P-value was determined by log-rank test and represents a comparison of overall survival in the Delta-24-RIVER-treated mice with that in UVi-inactivated Delta-24-RIVER-treated mice. Note that two Delta-24-RIVER-treated animals and none of the UVi-treated animals were censored at the end of the experiment.
Oncolytic adenovirus retargeted to EGFRvIII Y Piao et al cells to adenoviral infection. Our results are significant for two reasons: first, because EGFR amplification is one of the hallmarks of the molecular signature of the most frequent primary malignant brain tumors, and second, because expression of the cancer-specific receptor EGFRvIII has not been documented in normal cells. Collectively, our data showed the resulting oncolytic adenovirus is capable of highly specific infectivity, without a lessening of the replication phenotype, and has a potent anti-glioma effect in vitro and in vivo.
Because of the paucity of CAR in glioma cells, oncolytic adenoviruses need to be retargeted to achieve a significant anticancer effect in vivo. However, this is not an easy task, as few modifications of the fiber might compromise both an efficient assembly and a potent viral replication. 4 As a result, there are few oncolytic adenoviruses that can be targeted to gliomas and fully develop a replication phenotype. 4, 7 Other earlier reported oncolytic adenoviruses with the ability to infect CAR-negative tumor cells include those with a cyclic RGD peptide inserted into the fiber HI loop, lysine residues added to the carboxy terminus of the fiber protein, and Ad5/Ad3 or Ad5/Ad35 fiber chimeras. [20] [21] [22] [23] Perhaps, the bestcharacterized of these adenoviruses is Delta-24-RGD, 7, 23 which will soon be tested clinically. With regard to tropism modifications, Delta-24-RGD and Delta-24-RIVER are at opposite ends of the oncolytic adenovirus spectrum. Specifically, the RGD-4C-modification has been designed to induce binding and internalization through RGD-related integrins and thereby powerfully enhance the tropism with universal infectivity. 7, 23 On the other hand, Delta-24-RIVER has been designed to infect EGFRvIII-expressing cells with exquisite specificity, with only a minor and, indeed, desirable leakage into cells overexpressing EGFR. Thus, glioblastomas with amplified EGFR and encompassing EGFRvIII mutations should be optimum targets for Delta-24-RIVER treatment; this strategy is also preferable to Delta-24-RGD treatment in patients with these tumors because it can be administered at high doses with negligible toxicity.
Because EGFR overexpression has been reported for many types of humans cancers, including gliomas, efforts have been made to develop agents that can target this receptor; this has included a search for small-molecule inhibitors specific to EGFRvIII and the generation of EGFRvIII-specific antibody-based therapies. 5, 24, 25 The disadvantage of these two approaches, however, is that they target a specific mutant protein in a pathway that is normally overridden by the activation of pathways with overlapping functions. 3 The oncolytic effect in this context is more potent than the pharmacological one, because, once the cell is infected, the adenovirus is able to control the main regulators of the cell machinery and thus able to induce cell death independently of the genetic makeup of the host.
Although previous efforts have been made to target EGFR using viral vectors, [26] [27] [28] [29] our group is the first to have generated a new oncolytic adenovirus, Delta-24-RIVER, with tropism redirected to EGFRvIII that is able to acquire a full replication phenotype in cells expressing EGFRvIII but only low levels of CAR. Using two isogenic cell line systems, we dissected the pathways responsible for the infectivity of the adenovirus to clearly show the need for EGFRvIII for optimum infectivity. In addition, we showed that cells expressing high levels of wild-type EGFR (mimicking the amplification and/or overexpression of EGFR observed in most malignant gliomas) are receptive to infection by Delta-24-RIVER, albeit with less efficiency than the ones expressing the mutant form, but enough to induce an anti-glioma effect. These observations have important implications for therapy because it is thought that cells expressing different forms of EGFR are part of the brain tumor cell population and that these cells are responsible for tumor recurrence after therapy and the ultimate death of the patient. 30 In summary, Delta-24-RIVER has a selective and potent anti-glioma effect. Our ultimate goal is to translate our laboratory findings regarding oncolytic adenoviruses into therapies appropriate for clinical use. Delta-24-RIVER is well suited to this objective, and our findings are grounds for the initiation of a phase I clinical trial to test its toxicity and efficacy in patients with recurrent malignant gliomas. Because EGFRvIII has been shown to confer resistance to both radiotherapy and chemotherapy, 31 ,32 the targeting of this molecule is of great clinical relevance. 33 In fact, this agent could be used in tumors resistant to anti-EGFR therapies, since a recent study of GBM patients found that EGFRvIII in combination with the loss of the PTEN tumor suppressor gene resulted in resistance to second-generation cancer therapeutics targeting EGFR. 34 Another aspect to consider in the clinical setting is the role played by the immunity on the efficacy of Delta-24-RIVER. In this regard, as is contemplated in other virotherapy strategies, 35 the combination of immunosuppressant together with oncolytic adenoviruses might be considered in the future.
